What is the recommended diagnostic workup for inguinal adenopathy due to adenocarcinoma of unknown primary?

Workup for Inguinal Adenopathy from Adenocarcinoma of Unknown Primary

For inguinal adenopathy due to adenocarcinoma of unknown primary, perform core needle biopsy with comprehensive immunohistochemistry, CT chest/abdomen/pelvis, and targeted laboratory studies including PSA in males and hormone receptors in females, while avoiding routine PET/CT and limiting endoscopies to symptom-directed investigations only. 1

Initial Tissue Diagnosis

The cornerstone of workup is obtaining adequate tissue for pathologic evaluation:

• Core needle biopsy is preferred over fine needle aspiration to provide sufficient material for immunohistochemistry 1
• Consult pathology immediately for specimen adequacy assessment
• Request comprehensive immunohistochemical staining upfront to avoid repeat biopsies

Essential Immunohistochemistry Panel

For adenocarcinoma presenting in inguinal nodes, the IHC strategy must identify treatable primaries:

In males:

• PSA and/or PSMA/NKX3.1 to exclude prostate cancer (critical for hormone-sensitive disease) 2, 3
• CK7 and CK20 staining patterns to suggest tissue of origin 2

In females:

• Estrogen and progesterone receptors (mandatory for axillary presentations, reasonable for inguinal) 2, 3
• GATA3 for breast cancer screening 4
• Consider SOX10 for triple-negative breast cancer 4

For all patients:

• CK7/CK20 pattern analysis
• CDX2 and SATB2 if colorectal primary suspected 4
• TTF1 if lung primary considered 4

Mandatory Imaging and Laboratory Studies

Standard imaging workup:

• CT chest/abdomen/pelvis (constitutes minimal basic workup) 1, 2
• Avoid routine PET/CT - it is not recommended for standard management and should only be used in select situations 1

Laboratory evaluation:

• CBC, comprehensive metabolic panel, liver function tests, creatinine, calcium 1
• Fecal occult blood test 2, 3
• Urinalysis 2, 3

Tumor markers (selective, not routine):

• PSA in males (essential to identify treatable prostate cancer) 2, 3
• AFP and beta-HCG in males with midline or atypical presentations to exclude germ cell tumors 2, 3

Physical Examination Priorities

Focus the examination on identifying occult primaries that drain to inguinal nodes:

• Genitourinary examination (penis, scrotum, prostate in males; vulva, vagina, cervix in females)
• Pelvic and rectal examination (mandatory) 1, 2
• Skin examination of lower extremities and perineum (melanoma consideration)
• Review any history of spontaneously regressing lesions or previously removed lesions 1

Endoscopy Strategy

Endoscopies must be symptom-directed only - do not perform routine pan-endoscopy 1, 2, 3. This represents a critical pitfall to avoid, as extensive endoscopic evaluation rarely identifies primaries in asymptomatic patients and delays treatment initiation.

Perform endoscopy only if:

• Gastrointestinal symptoms present
• Fecal occult blood positive
• IHC pattern strongly suggests GI primary (CK20+/CK7-/CDX2+)

What NOT to Do

Several common practices should be avoided based on guideline evidence:

• Do not order gene signature profiling for tissue of origin - this is a Category 3 recommendation (major disagreement) and not recommended for standard management 1
• Do not perform routine PET/CT - reserve for specific scenarios only 1
• Do not pursue exhaustive endoscopic evaluation without symptoms or strong IHC evidence 1, 2
• Do not delay treatment while searching indefinitely for a primary site

Clinical Context for Inguinal Presentation

Inguinal adenopathy with adenocarcinoma is an uncommon presentation for CUP. The differential diagnosis includes:

• Genitourinary primaries (prostate, bladder, urethra)
• Gynecologic primaries (cervix, vulva, vagina)
• Anorectal adenocarcinoma
• Lower extremity melanoma (though typically not adenocarcinoma)
• Metastatic colorectal cancer via aberrant lymphatic drainage

The NCCN guidelines 1 emphasize that this workup should identify the minority of patients with treatable, potentially curable disease (hormone-sensitive prostate or breast cancer, germ cell tumors) while avoiding excessive testing that delays systemic therapy in patients with unfavorable prognosis.

Prognostic Considerations

Recognize that CUP carries poor prognosis overall (median survival ~3 months), with approximately 50% of deaths occurring within the first 3 months of diagnosis 4. This underscores the importance of efficient workup without unnecessary delays. Patients presenting with nodal-only disease have better prognosis than those with visceral metastases 4.